Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Developing a More Positive Approach

Not a member of My prIME? Join now for instant access.

Meeting Overview

View the poster gallery and interact with the experts at our symposium as they discuss therapeutic options for triple-negative breast cancer. Topics to be discussed include the biology of triple-negative breast cancer, current treatment options, novel targeted treatments, PARP inhibitors, and immunotherapy.

A prIME Oncology satellite symposium to be held in conjunction with the 2018 San Antonio Breast Cancer Symposium (SABCS).

Date and Location

Wednesday, December 5, 2018
7.30 PM – 10.00 PM

Grand Ballroom, Salons H & I
Marriott Rivercenter
101 Bowie Street
San Antonio, Texas, United States



Wednesday, December 5, 2018
7.30 PM – 10.00 PM



San Antonio, Texas, United States



1.75 AMA PRA Category 1 Credits™

7.30 PM Registration, poster viewing, and dinner
8.15 PM Welcome, introduction, and triple-negative breast cancer quiz
Robert Coleman, MD, FRCP, FRCPE
8.20 PM Understanding what triple-negative breast cancer is rather than what it isn’t!
Jorge Reis-Filho, MD, PhD, FRCPath
8.35 PM Outcomes for patients with triple-negative breast cancer and current treatment options
Denise Yardley, MD
8.50 PM Interactive faculty discussion and questions
8.55 PM Smart weapons to attack triple-negative breast cancer
Adam Brufsky, MD, PhD, FACP
9.10 PM Interactive faculty discussion and questions
9.15 PM If it’s broken, break it again: Exploiting DNA repair mechanisms in breast cancer management
Jennifer Litton, MD
9.30 PM Interactive faculty discussion and questions
9.35 PM Harnessing the immune response in triple-negative breast cancer: Lessons learned and future challenges
Peter Schmid, MD, PhD, FRCP
9.50 PM Interactive faculty discussion and questions
9.55 PM Conclusions and prIME Points™
Robert Coleman, MD, FRCP, FRCPE
10.00 PM Adjourn


  • Robert Coleman, MD, FRCP, FRCPEMedical Director, prIME Oncology
    University of Sheffield
    Weston Park Hospital
    Sheffield, United Kingdom
  • Faculty

  • Adam Brufsky, MD, PhD, FACPUniversity of Pittsburgh
    Pittsburgh, Pennsylvania, United States
  • Jennifer Litton, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, Unites States
  • Jorge S. Reis-Filho, MD, PhD, FRCPathMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Peter Schmid, MD, PhD, FRCPQueen Mary University of London
    Barts Hospital
    London, United Kingdom
  • Denise Yardley, MDSarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee, United States

This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals who treat/manage patients with triple-negative breast cancer

After successful completion of this educational activity, participants should be able to:

  • Describe the biologic and molecular features of triple-negative breast cancer that serve as potential biomarkers and therapeutic targets
  • Design optimal treatment strategies for patients with triple-negative breast cancer based on current guidelines, clinical trial data, and patient and disease characteristics
  • Analyze the rationale for novel treatment approaches for triple-negative breast cancer and recent clinical trial data investigating these agents, including targeted therapies and immunotherapies

This educational activity is supported by grants from AstraZeneca; Celgene Corporation; and Merck and Co, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Jaye Harden prior to the live event at 678.892.1353.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.